/

After years of lobbying, drug researchers hail Washington's decision as a major policy shift

Vets with PTSD given OK to take pot

AP

The U.S. government has signed off on a long-delayed study looking at marijuana as a treatment for military veterans with post-traumatic stress disorder, a development that drug researchers are hailing as a major shift in U.S. policy.

The Department of Health and Human Services’ decision surprised marijuana advocates who have struggled for decades to secure federal approval for research into the drug’s medical uses.

The proposal from the University of Arizona was long ago cleared by the Food and Drug Administration, but researchers had been unable to purchase marijuana from the National Institute on Drug Abuse (NIDA). The agency’s Mississippi research farm is the only federally sanctioned source of the drug.

In a letter last week, HHS cleared the purchase of medical marijuana by the studies’ chief financial backer, the Multidisciplinary Association for Psychedelic Studies, which supports medical research and legalization of marijuana and other drugs.

“MAPS has been working for over 22 years to start marijuana drug development research, and this is the first time we’ve been granted permission to purchase marijuana from NIDA,” the Boston-based group said in a statement. The federal government has never before approved medical research involving smoked or vaporized marijuana, according to MAPS.

A spokesman for the group said organizers have called off a protest over the stalled study that was planned for later this year.

While more than 1 million Americans take medical marijuana — usually for chronic pain — rigorous medical research into the drug’s effects has been limited, in part due to federal restrictions.

Marijuana remains a Schedule I substance under the federal government’s Controlled Substance Act. That means the drug is considered a high risk for abuse with no accepted medical applications.

In the past, NIDA has focused its research on the risks of drug abuse and addiction, turning away researchers interested in studying the potential benefits of illegal substances.

Even with the latest green light from HHS, MAPS and University of Arizona professor Suzanne Sisley must still get approval from the Drug Enforcement Administration, though they expect that clearance to come more quickly.